Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Roche Media News
Get the latest updates from Roche Media News directly as they happen.
Follow now 526 followers
Latest posts
Last updated about 17 hours ago
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity
about 17 hours ago
At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction...
European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)
1 day ago
By continuously delivering medicine into the eye through the Contivue refillable implant...
CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis
4 days ago
Ocrevus addresses a critical need in paediatric neurology as the first high-...
Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases
5 days ago
The center will be a hub for Roche and Genentech, bringing together...
Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study
6 days ago
Phase III CELESTIMO study met its primary endpoint at the interim analysis...
Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
10 days ago
Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase...
U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments
13 days ago
If approved, Enspryng would be the first and only disease-modifying therapy for...
Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)
26 days ago
The SALWEEN study showed significant improvements in vision and retinal health1 More...
Roche’s US subsidiary Genentech announces manufacturing expansion in the United States
about 1 month ago
New facility in Hillsboro, Oregon for the assembly of injectable medicines and...
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
2 months ago
Susvimo is the first and only continuous delivery treatment that offers an...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
2 months ago
Group sales were +6% at constant exchange rates (CER)1, -2% when reported...
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy
2 months ago
Priority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro...